Low Percentage of Signal Regulatory Protein α/β+ Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients

Low Percentage of Signal Regulatory Protein α/β+ Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients

An important goal for personalized treatment is predicting response to a particular therapeutic. A drawback of biological treatment is immunogenicity and the development of antibodies directed against the drug [anti-drug antibodies (ADA)], which are associated with a poorer clinical outcome. Here we...

Повний опис

Бібліографічні деталі
Автори: Laura Magill, Marsilio Adriani, Véronique Berthou, Keguan Chen, Aude Gleizes, Salima Hacein-Bey-Abina, Agnes Hincelin-Mery, Xavier Mariette, Marc Pallardy, Sebastian Spindeldreher, Natacha Szely, David A. Isenberg, Jessica J. Manson, Elizabeth C. Jury, Claudia Mauri
Формат: Стаття
Мова:English
Опубліковано: Frontiers Media S.A. 2018-12-01
Серія:Frontiers in Immunology
Предмети:
B cells
rheumatoid arthritis
anti-drug antibodies
immunogenicity
SIRP
anti-TNF
Онлайн доступ:https://www.frontiersin.org/article/10.3389/fimmu.2018.02865/full

Інтернет

https://www.frontiersin.org/article/10.3389/fimmu.2018.02865/full

Схожі ресурси